Transmucular Quadratus Lumborum Block: Potential Quadriceps Muscle Weakness

• Status: Not yet recruiting
• Trial end date: 2021-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to examine whether the administration of the TQL block cause motor block of the lumbar plexus and thereby quadriceps muscle weakness. The investigators hypothesise that the administration of a unilateral TQL block does not cause quadriceps muscle weakness compared to a placebo block.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Zealand University Hospital
• Treatments: Ropivacaine

Criteria

Inclusion Criteria:

• Age ≥ 18 years

• American Associations of Anaesthesiologist (ASA) class 1-2

• Have received written and oral information and signed the consent form

• Weight > 56,5 kilograms (Chosen due to maximum single dose of ropivacaine i.e. 225 milligrams)

Exclusion Criteria:

• Inability to speak and understand Danish

• Inability to cooperate

• Allergy to study drugs

• Daily intake of opioids

• Alcohol and/or drug overuse

• Fertile female participants: No use of safe contraceptives for the last month, positive urine-HCG or breastfeeding

• Previous trauma of surgery in the abdomen, hip or knee.

• Any systemic muscular or neuromuscular disease